PT - JOURNAL ARTICLE AU - Abela, Irene A. AU - Pasin, Chloé AU - Schwarzmüller, Magdalena AU - Epp, Selina AU - Sickmann, Michèle E. AU - Schanz, Merle M. AU - Rusert, Peter AU - Weber, Jacqueline AU - Schmutz, Stefan AU - Audigé, Annette AU - Maliqi, Liridona AU - Hunziker, Annika AU - Hesselman, Maria C. AU - Niklaus, Cyrille R. AU - Gottschalk, Jochen AU - Schindler, Eméry AU - Wepf, Alexander AU - Karrer, Urs AU - Wolfensberger, Aline AU - Rampini, Silvana K. AU - Meyer Sauteur, Patrick M. AU - Berger, Christoph AU - Huber, Michael AU - Böni, Jürg AU - Braun, Dominique L. AU - Marconato, Maddalena AU - Manz, Markus G. AU - Frey, Beat M. AU - Günthard, Huldrych F. AU - Kouyos, Roger D. AU - Trkola, Alexandra TI - Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity AID - 10.1101/2021.04.21.21255410 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.21.21255410 4099 - http://medrxiv.org/content/early/2021/11/18/2021.04.21.21255410.short 4100 - http://medrxiv.org/content/early/2021/11/18/2021.04.21.21255410.full AB - Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to circulating human coronavirus (HCoV) is critical to understanding protective immunity. Here we perform a multifactorial analysis of SARS-CoV-2 and HCoV antibody responses in pre-pandemic (N=825) and SARS-CoV-2-infected donors (N=389) using a custom-designed multiplex ABCORA assay. ABCORA seroprofiling, when combined with computational modeling, enables accurate definition of SARS-CoV-2 seroconversion and prediction of neutralization activity, and reveals intriguing interrelations with HCoV immunity. Specifically, higher HCoV antibody levels in SARS-CoV-2-negative donors suggest that preexisting HCoV immunity may provide protection against SARS-CoV-2 acquisition. In those infected, higher HCoV activity is associated with elevated SARS-CoV-2 responses, indicating cross-stimulation. Most importantly, HCoV immunity may impact disease severity, as patients with high HCoV reactivity are less likely to require hospitalization. Collectively, this evidence points to HCoV immunity promoting the rapid development of SARS-CoV-2-specific immunity, underscoring the importance of exploring cross-protective responses for comprehensive coronavirus prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant of the Pandemiefonds of the University of Zurich Foundation to A.T., a grant of the Swiss Red Cross to B.F. and A.T., a grant of the University Hospital Zurich Innovation Grant to M.G.M., the Swiss National Science Foundation grant 31CA30_196906 to H.F.G., A.T., R.K. and the Gilead COVID-19 RFP Research Program COMMIT Grant #: IN-SW-983-6078 (to H.F.G., A.T., R.K.). I.A.A. is supported by a research grant of the Promedica Foundation. Roche Diagnostics supported the study with providing test material for a proportion of the Elecsys S tests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum and plasma samples collected pre and post emergence of SARS-CoV-2 in Switzerland (pre and post February 2020, respectively) were included. No patient enrollment was conducted for the present study. All experiments involving samples from human donors were conducted with the approval of the responsible local ethics committee (Kantonale Ethikkommission) Zurich, Switzerland (BASEC Nrs 2020-01327, 2020-00363; 2021-00437; 2020-00787), in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation. Samples were obtained from the following sources: i) Zurich blood donation services (ZHBDS): Anonymized healthy adult plasma from pre-pandemic time points (January 2019, May 2019 and January 2020) and from the first wave of the pandemic in Zurich, Switzerland (May 2020) were provided by the ZHBDS internal serum repository and consent for this study was waived by the ethics committee (BASEC 2021-00437). ii) Anonymized leftover specimens from routine diagnostics at the Institute of Medical Virology, University of Zurich, the University Children Hospital Zurich and the Cantonal Hospital Winterthur (BASEC Nrs 2020-01327, 2021-00437). Written informed consent was obtained from all participants whose sample was taken during the pandemic at the University Hospital Zurich (BASEC 2020-01327). For pandemic samples from other hospitals and pre-pandemic samples consent was waived by the ethics committee. iii) Healthcare workers with RT-PCR confirmed SARS-CoV-2 infection participating in a study at the University Hospital Zurich (BASEC 2020-00363). Written informed consent was obtained from all participants. iv) Male plasma donors participating in a SARS-CoV-2 plasma therapy study conducted at the University Hospital Zurich (CPT-ZHP, Swissmedic 2020TpP1004; BASEC 2020-00787). Written informed consent for research was obtained from all participants. The reporting of all human and patient data is in compliance with STROBE statement.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data will be available in the peer-reviewed journal version.